Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/22633
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | DIAS, C. Bitencourt | - |
dc.contributor.author | PINHEIRO, C. C. | - |
dc.contributor.author | MALAFRONTE, P. | - |
dc.contributor.author | TITAN, S. | - |
dc.contributor.author | BRITO, G. Alves de | - |
dc.contributor.author | ABRAO, J. Gera | - |
dc.contributor.author | SILVA, V. dos Santos | - |
dc.contributor.author | BARROS, R. Toledo | - |
dc.contributor.author | WORONIK, V. | - |
dc.date.accessioned | 2017-11-27T16:23:34Z | - |
dc.date.available | 2017-11-27T16:23:34Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | CLINICAL NEPHROLOGY, v.76, n.1, p.57-63, 2011 | - |
dc.identifier.issn | 0301-0430 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/22633 | - |
dc.description.abstract | The treatment of membranous lupus nephritis (MLN) is still controversial in the literature. We conducted a retrospective analysis of patients in two medical centers of Sao Paulo-Brazil in order to evaluate the clinical response in patients submitted to either a regimen with prednisone alone or to a double immunosuppressive regimen (prednisone plus cyclophosphamide or prednisone plus azathioprine). Methods: MLN female patients were enrolled in this retrospective study conducted from February 1999 to June 2007. Data were collected from the patients' medical charts. Race distribution was similar in both groups: Caucasian (72.3%) and Afro-Latin-American (27.7%). The prednisone regimen consisted of 1 mg/kg/day for 8 weeks and tapering until 0.1 mg/kg/day (n = 29). The double immunosuppressive treatment consisted of the same doses of prednisone plus monthly intravenous cyclophosphamide or azathioprine for 6 months (n = 24). Criteria for remission (complete and partial) and renal function loss as well as flare criteria followed those used in the literature. Results: There was no difference between the prednisone group and the double immunosuppressive group regarding age (33.2 +/- 9.4 vs. 29.1 +/- 9.1 y), estimated GFR (76.5 +/- 26.6 vs. 74.1 +/- 39.6 ml/min/1.73 m(2)), serum albumin (2.8 +/- 0.7 vs. 2.6 +/- 0.3 g/dl), positive ANA (87.5 vs. 90.0%), positive anti-dsDNA (47.6 vs. 44.0%), renal SLEDAI indices (6.6 +/- 2.6 vs. 7.0 +/- 3.1), follow-up time (71 +/- 46 vs. 62 +/- 45 months), as well as proteinuria (3.1 +/- 1.9 vs. 4.8 +/- 2.4 g/day) and number of non-nephrotic patients (6 in the prednisone group vs. 3 in the double immunosuppressive group). The prednisone group presented higher C3 values (85.2 +/- 31.5 vs. 62.3 +/- 41.6 U/ml, p = 0.04). Clinical and laboratory characteristics at 6 months and at last follow-up did not reveal any differences between treatment regimens. Renal survival after an 8-year follow-up did not differ in both groups (prednisone group 86.2% vs. double immunosuppressive group 75%), and patients in both groups showed a high rate of renal flares (prednisone group 51.7% vs. double immunosuppressive group 62.5%). Univariate analysis showed that only patient age predicted flares (r = -0.048, p = 0.04). Borderline significance was obtained for proteinuria analysis (p = 0.07). Adverse effects did not differ between the groups. Conclusions: A regimen of corticosteroids in MLN induced a high remission rate after 6 months. Both treatment regimens showed a high flare rate and age was the only predictive parameter (r = -0.048, p = 0.04). Renal survival after 8 years did not differ between the groups. | - |
dc.language.iso | eng | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.relation.ispartof | Clinical Nephrology | - |
dc.rights | restrictedAccess | - |
dc.subject | lupus nephritis | - |
dc.subject | immunosuppressive drugs | - |
dc.subject | membranous nephropathy | - |
dc.subject | proteinuria | - |
dc.subject | epidemiology | - |
dc.subject.other | nephropathy | - |
dc.subject.other | erythematosus | - |
dc.subject.other | classification | - |
dc.subject.other | glomerulonephritis | - |
dc.subject.other | cyclosporine | - |
dc.subject.other | therapy | - |
dc.subject.other | trial | - |
dc.title | Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis | - |
dc.type | article | - |
dc.rights.holder | Copyright DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.identifier.doi | 10.5414/CN106689 | - |
dc.identifier.pmid | 21722606 | - |
dc.subject.wos | Urology & Nephrology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | DIAS, C. Bitencourt:Univ Sao Paulo, Dept Internal Med, Div Nephrol, Sao Paulo, Brazil | - |
hcfmusp.author.external | PINHEIRO, C. C.:Univ Sao Paulo, Dept Internal Med, Div Nephrol, Sao Paulo, Brazil | - |
hcfmusp.author.external | BRITO, G. Alves de:Univ Estadual Paulistana, Hosp Clin, Fac Botucatu, Dept Internal Med, Sao Paulo, Brazil | - |
hcfmusp.author.external | ABRAO, J. Gera:Univ Estadual Paulistana, Hosp Clin, Fac Botucatu, Dept Internal Med, Sao Paulo, Brazil | - |
hcfmusp.author.external | SILVA, V. dos Santos:Univ Estadual Paulistana, Hosp Clin, Fac Botucatu, Dept Internal Med, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 57 | - |
hcfmusp.description.endpage | 63 | - |
hcfmusp.description.issue | 1 | - |
hcfmusp.description.volume | 76 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000293453100007 | - |
hcfmusp.origem.id | 2-s2.0-80051755295 | - |
hcfmusp.publisher.city | DEISENHOFEN-MUENCHEN | - |
hcfmusp.publisher.country | GERMANY | - |
hcfmusp.relation.reference | Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D | - |
hcfmusp.relation.reference | Sun HO, 2008, LUPUS, V17, P56, DOI 10.1177/0961203307083443 | - |
hcfmusp.relation.reference | Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928 | - |
hcfmusp.relation.reference | Markowitz GS, 2007, KIDNEY INT, V71, P491, DOI 10.1038/sj.ki.5002118 | - |
hcfmusp.relation.reference | Austin HA, 2009, J AM SOC NEPHROL, V20, P901, DOI 10.1681/ASN.2008060665 | - |
hcfmusp.relation.reference | Mok CC, 2004, AM J KIDNEY DIS, V43, P269, DOI 10.1053/j.ajkd.2003.10.029 | - |
hcfmusp.relation.reference | Mok CC, 2009, NAT REV NEPHROL, V5, P212, DOI 10.1038/nrneph.2009.14 | - |
hcfmusp.relation.reference | Austin HA, 2005, LUPUS, V14, P65, DOI 10.1191/0961203305lu2062oa | - |
hcfmusp.relation.reference | Balow JE, 2003, SEMIN NEPHROL, V23, P386, DOI 10.1016/S0270-9295(03)00056-1 | - |
hcfmusp.relation.reference | Chan TM, 1999, LUPUS, V8, P545, DOI 10.1191/096120399678840837 | - |
hcfmusp.relation.reference | Churg J, 1995, RENAL DIS CLASSIFICA | - |
hcfmusp.relation.reference | JACOBSON SH, 2006, NEPHROL DIAL TRANSPL, V23, P1 | - |
hcfmusp.relation.reference | Kapitsinou PP, 2004, RHEUMATOLOGY, V43, P377, DOI 10.1093/rheumatology/keh012 | - |
hcfmusp.relation.reference | Kitiyakara C, 2008, CLIN NEPHROL, V69, P90 | - |
hcfmusp.relation.reference | Mercadal L, 2002, NEPHROL DIAL TRANSPL, V17, P1771, DOI 10.1093/ndt/17.10.1771 | - |
hcfmusp.relation.reference | Moroni G, 1998, AM J KIDNEY DIS, V31, P681, DOI 10.1053/ajkd.1998.v31.pm9531186 | - |
hcfmusp.relation.reference | PASQUALI S, 1993, CLIN NEPHROL, V39, P175 | - |
hcfmusp.relation.reference | PASTEN VR, 2005, REV MED CHILE, V133, P23 | - |
hcfmusp.relation.reference | RADHAKRISHNAN J, 1994, CLIN NEPHROL, V42, P147 | - |
hcfmusp.relation.reference | Spetie DN, 2004, KIDNEY INT, V66, P2411, DOI 10.1111/j.1523-1755.2004.66030.x | - |
dc.description.index | MEDLINE | - |
hcfmusp.citation.scopus | 5 | - |
hcfmusp.scopus.lastupdate | 2024-03-28 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/16 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.